

Global Impact of the COVID-19 Pandemic on Stroke Hospitalizations and Mechanical Thrombectomy Volumes

Journal:	<i>International Journal of Stroke</i>
Manuscript ID	IJS-12-20-8762.R1
Manuscript Type:	Research
Date Submitted by the Author:	07-Jan-2021
Complete List of Authors:	Nogueira, Raul; Emory University, Raul Nogueira


	<p>Abdalkader, Mohamad; Boston Medical Center Qureshi, Muhammed; Boston Medical Center Frankel, MR; Grady Memorial Hospital, Neurology Mansour, Ossama; Alexandria University Yamagami, Hiroshi; National Hospital Organization Osaka National Hospital, Neurology Qiu, Zhongming; Xinqiao Hospital, Neurology; The 903th hospital of PLA, Neurology Farhoudi, Mehdi; Tabriz University of Medical Sciences, Neurosciences Siegler, James; Cooper University Health Care, Stroke Program, Department of Neurology Yaghi, Shadi; New York University, Neurology Raz, Eytan; NYU Langone Health Sakai, Nobuyuki; Kobe City Medical Center General Hospital, Neurosurgery Ohara, Nobuyuki; Kobe City Medical Center General Hospital, Comprehensive Stroke Center; Osaka Minami Medical Center, Division of Stroke Medicine Piotin, Michel; Fondation Ophtalmologique Adolphe de Rothschild, Interventional Neuroradiology Mechtouff, Laura; Université de Lyon 1, Stroke Unit, Hôpital Neurologique Pierre Wertheimer, Neurology Eker, Omer; Centre Hospitalier Lyon, Neuroradiology; Hopital Neurologique et Neurochirurgical Pierre Wertheimer Chalumeau, Vanessa; Centre Hospitalier Universitaire de Bicêtre, Neuroradiology Kleinig, Timothy; Royal Adelaide Hospital, Neurology Department Liu, Jian-Min; Second Military Medical University, Neurosurgery Pop, Raoul; University Hospitals Strasbourg, Department of Interventional Neuroradiology Winters, Hugh; Royal Prince Alfred Hospital Shang, Xianjin; Yijishan Hospital of Wannan Medical College, Neurology Rodriguez Vasquez, Alejandro; Hospital Clinic de Barcelona, Neurology Blasco, Jordi; Hospital Clinic de Barcelona, Interventional Neuroradiology Arenillas, Juan; Hospital Clínico Universitario, Neurology. Stroke Unit Martinez-Galdamez, Mario; Hospital Clinico Universitario de Valladolid, Interventional Neuroradiology Brehm, Alex; University Hospital Basel Psychogios, Marios; University of Basel Lylyk, Pedro; Clinica Sagrada Familia Haussen, Diogo; Emory University School of Medicine, Neurology Al-Bayati, Alhamza; Emory University, Neurology Mohammaden, Mahmoud; Emory University School of Medicine, Neurology; Grady Memorial Hospital, Fonseca, Luisa; Centro Hospitalar de São João EPE Silva, Maria Luí; Centro Hospitalar de Sao Joao EPE Montalverne, Francisco; Hospital Geral de Fortaleza, Neurointerventional Radiology Service Lima, Fabricio; Hospital Geral de Fortaleza, Neurology Renieri, Leonardo; University Hospital Careggi Mangiafico, Salvatore; University Hospital Careggi Fischer, Urs; Inselspital Bern, Universitätsklinik für Neurologie Gralla, Jan; Inselspital University Hospital Bern Frei, Donald; Colorado Neurological Institute, Neuroradiology Chugh, Chandril; Max Super Speciality Hospital Saket Mehta, Brijesh; Memorial Neuroscience Insitute Nagel, Simon; University of Heidelberg, Department of Neurology Möhlenbruch, Markus; University of Heidelberg, Neuroradiology Ortega, Santiago; University of Iowa, Neurology Farooqui, Mudassir; University of Iowa Hospitals and Clinics, Hassan, Ameer; Valley Baptist Medical Center - Harlingen</p>
--	--

	<p>Taylor, Allan; University of Cape Town Lapergue, bertrand; Foch Hospital, University Versailles Saint-Quentin en Yvelines, Department of Neurology Consoli, Arturo; Hopital Foch, Neuroradiology Campbell, Bruce; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Sharma, Malveeka; University of Washington Walker, Melanie; University of Washington van Horn, Noel; University Medical Center Hamburg-Eppendorf, Diagnostic and Interventional Neuroradiology Fiehler, Jens; University Medical Center Hamburg-Eppendorf, Neuroradiology Nguyen, Huy Thang; People's 115 Hospital Nguyen, Quoc; People's 115 Hospital Watanabe, Daisuke; IMS Tokyo-Katsushika General Hospital, Stroke and Neurovascular Surgery Zhang, Hao; Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Le, Huynh Vu; Hue Central Hospital Nguyen, Viet; Hue Central Hospital Shah, Ruchir; Erlanger Health System Devlin, Thomas; Erlanger North Hospital, Radiology Khandelwal, Priyank; Robert Wood Johnson University Hospital Linfante, Italo; Miami Cardiac & Vascular Institute Izzath, Wazim; Nottingham University Hospitals NHS Trust Lavados, Pablo; Clinica Alemana de Santiago SA, Neurología Olavarría, Veronica; Clinica Alemana de Santiago SA Sampaio Silva, Gisele; UNIFESP, Neurology Verena de Carvalho Sousa, Anna; Hospital Israelita Albert Einstein Kirmani, Jawad; Hackensack Meridian Health Inc Bendszus, Martin; University Hospital Heidelberg Amano, Tatsuo; Kyorin University, Stroke and Cerebrovascular Medicine Yamamoto, Ryoo; Yokohama Brain and Spine Center, Neurology Doijiri, Ryosuke; Iwate Prefectural Central Hospital Tokuda, Naoki; National Cerebral and Cardiovascular Center, Department of Cerebrovascular Medicine Yamada, Takehiro; Kyoto Second Red Cross Hospital, Neurology Terasaki, Tadashi; JAPANSE RED CROSS KUMAMOTO HOSPITAL, NEUROLOGY Yazawa, Yukako; Kohnan Hospital, Stroke Neurology Morris, Jane; Maine Medical Center, Neurology Griffin, Emma; Beaumont Hospital, Radiology Thornton, John; Beaumont Hospital, Department of Neuroradiology Lavoie, Pascale; Centre Hospitalier de l'Université Laval, Neurochirurgie Matouk, Charles; Yale School of Medicine, Neurosurgery Hill, Michael; University of Calgary, Clinical Neurosciences Demchuk, Andrew; Hotchkiss Brain Institute, Clinical Neurosciences; Cumming School of Medicine, University of Calgary, University of Calgary Killer, Monika; Christian Doppler Clinic, Paracelsus Medical University, Neuroscience Institute Salzburg, Department of Neurology Nahab, Fadi; Emory University Altschul, Dorothea; Neurosurgical Associates of New Jersey, Neuroscience Perez de la Ossa, Natalia; Hospital Germans Trias i Pujol Kikano, Raghid; LAU, Radiology Boisseau, William; Centre Hospitalier de l'Université de Montreal Walker, Gregory; Ottawa Hospital, Department of Medicine (Neurology) Cordina, Steve; University of South Alabama Puri, Ajit; New England Center for Stroke Research, University of Massachusetts Kuhn, Anna; University of Massachusetts Medical School, Radiology</p>
--	--

	Gandhi, Dheeraj; University of Maryland Baltimore Nguyen, Thanh; Boston Medical Center, Neurology;
Keywords:	COVID-19, mechanical thrombectomy, Intracerebral hemorrhage, Ischaemic stroke, Acute stroke therapy, Epidemiology




Figure 1. Weekly volume of stroke admissions (ischemic and hemorrhagic) and COVID-19 hospitalizations volumes.



* Peak of 1235 COVID hospitalizations in the second week of February, predominantly from one hospital in Wuhan, China.

Figure 2. Weekly volume of mechanical thrombectomy and COVID-19 hospitalizations.



* Peak of 1235 COVID hospitalizations in the second week of February, predominantly from one hospital in Wuhan, China.

Global Impact of COVID-19 on Stroke Care**Authors:** SVIN COVID-19 Global Registry

Raul G.Nogueira*¹, Mohamad Abdalkader², Muhammad Mustafa Qureshi², Michael Frankel¹, Ossama Y.Mansour^{3**}, Hiroshi Yamagami^{4#}, Zhongming Qiu⁵, Mehdi Farhoudi^{6**}, James E.Siegler⁷, Shadi Yaghi⁸, Eytan Raz⁸, Nobuyuki Sakai^{9#}, Nobuyuki Ohara^{9#}, Michel Piotin¹⁰, Laura Mechtouff¹¹, Omer Eker¹¹, Vanessa Chalumeau¹², Timothy J.Kleinig¹³, Raoul Pop¹⁴, Jianmin Liu¹⁵, Hugh S.Winters¹⁶, Xianjin Shang¹⁷, Alejandro Rodriguez Vasquez¹⁸, Jordi Blasco¹⁸, Juan F.Arenillas¹⁹, Mario Martinez-Galdamez¹⁹, Alex Brehm²⁰, Marios-Nikos Psychogios²⁰ Pedro Lylyk²¹, Diogo C.Haussen¹, Alhamza R.Al-Bayati¹, Mahmoud Mohammaden¹, Luísa Fonseca²², M Luís Silva²², Francisco Montalverne²³, Fabricio O.Lima²³, Leonardo Renieri²⁴, Salvatore Mangiafico²⁴, Urs Fischer²⁵, Jan Gralla²⁵, Donald Frei²⁶, Chandril Chugh²⁷, Brijesh P.Mehta²⁸, Simon Nagel²⁹, Markus Mohlenbruch²⁹, Santiago Ortega-Gutierrez³⁰, Mudassir Farooqui³⁰, Ameer E.Hassan³¹, Allan Taylor³², Bertrand Lapergue³³, Arturo Consoli³³, Bruce CV.Campbell³⁴, Malveeka Sharma³⁵, Melanie Walker³⁵, Noel Van Horn³⁶, Jens Fiehler³⁶, Huy Thang Nguyen³⁷, Quoc T.Nguyen³⁷, Daisuke Watanabe^{38#}, Hao Zhang³⁹, Huynh V.Le⁴⁰, Viet Q.Nguyen⁴⁰, Ruchir Shah⁴¹, Thomas Devlin⁴¹, Priyank Khandelwal⁴², Italo Linfante⁴³, Wazim Izzath⁴⁴, Pablo M.Lavados⁴⁵, Veronica V. Olavarría⁴⁵, Gisele Sampaio Silva^{46,47}, Anna Verena de Carvalho Sousa⁴⁷, Jawad Kirmani⁴⁸, Martin Bendszus²⁹, Tatsuo Amano^{49#}, Ryoo Yamamoto^{50#}, Ryosuke Doijiri^{51#}, Naoki Tokuda^{52#}, Takehiro Yamada^{53#}, Tadashi Terasaki^{54#}, Yukako Yazawa^{55#}, Jane Morris⁵⁶, Emma Griffin⁵⁷, John Thornton⁵⁷, Pascale Lavoie⁵⁸, Charles Matouk⁵⁹, Michael D.Hill⁶⁰, Andrew M.Demchuk⁶⁰, Monika Killer-Oberpfalzer⁶¹, Fadi Nahab⁶², Dorothea Altschul⁶³, Natalia Pérez de la Ossa⁶⁴, Raghid Kikano⁶⁵, William Boisseau⁶⁶, Gregory Walker⁶⁷, Steve M. Cordina⁶⁸, Ajit Puri⁶⁹, Anna Luisa Kuhn⁶⁹, Dheeraj Gandhi⁷⁰, Pankajavalli Ramakrishnan⁷¹, Roberta Novakovic-White⁷², Alex Chebl⁷³, Odysseas Kargiotis⁷⁴, Alexandra Czap⁷⁵, Alicia Zha⁷⁵, Hesham Masoud⁷⁶, Carlos Lopez⁷⁶, David Ozretic⁷⁷, Fawaz Al-Mufti⁷⁸, Wenjie Zie⁵, Zhenhui Duan⁷⁹, Zhengzhou Yuan⁸⁰, Wenguo Huang⁸¹, Yonggang Hao⁸², Jun Luo⁸³, Vladimir Kalousek⁸⁴, Romain Bourcier⁸⁵, Romain Guile⁸⁵, Steven Hetts⁸⁶, Hosam M. Al-Jehani^{87**}, Adel AlHazzani^{88**}, Elyar Sadeghi-Hokmabadi^{6**}, Mohamed Teleb⁸⁹, Jeremy Payne⁸⁹, Jin Soo Lee⁹⁰, Ji Man Hong⁹⁰, Sung-Il Sohn⁹¹, Yang-ha Hwang⁹², Dong Hun Shin⁹³, Hong Gee Roh⁹⁴, Randy Edgell⁹⁵, Rakesh Khatri⁹⁶, Ainsley Smith⁷, Amer Malik⁹⁷, David Liebeskind⁹⁸, Nabeel Herial⁹⁹, Pascal Jabbour⁹⁹, Pedro Magalhaes¹⁰⁰, Atilla Ozcan Ozdemir^{101**}, Ozlem Aykac^{101**}, Takeshi Uwatoko^{102#}, Tomohisa Dembo^{103#}, Hisao Shimizu^{104#}, Yuri Sugiura^{105#}, Fumio Miyashita^{106#}, Hiroki Fukuda^{107#}, Kosuke Miyake^{108#}, Junsuke Shimbo^{109#}, Yusuke Sugimura^{110#}, Andre Beer-Furlan¹¹¹, Krishna Joshi¹¹¹, Luciana Catanese¹¹², Daniel Giansante Abud¹¹³, Octavio Pontes Neto¹¹³, Masoud Mehrpour^{114**}, Amal Al Hashmi^{115**}, Mahar Saqqr^{116**}, Abdulrahman Mostafa^{3,116**}, Johanna Fifi¹¹⁷, Syed Hussain^{118**}, Seby John^{118**}, Rishi Gupta¹¹⁹, Rotem Sivan-Hoffmann¹²⁰, Anna Reznik¹²⁰, Achmad Fidaus Sani^{121**}, Serdar Geyik¹²², Eşref Akil¹²², Anchalee Churojana^{123**}, Abdoreza Ghoreishi^{124**}, Mohammad Saadatnia^{125**}, Ehsan Sharifipour^{126**}, Alice Ma¹²⁷, Ken Faulder¹²⁷, Teddy Wu¹²⁸, Lester Leung¹²⁹, Adel Malek¹³⁰, Barbara Voetsch¹³⁰, Ajay Wakhloo¹³⁰, Rodrigo Rivera¹³¹, Danny Moises Barrientos Iman¹³², Aleksandra Pikula¹³³, Vasileios-Arsenios Lioutas¹³⁰, Gotz Thomalla²⁸, Lee Birnbaum¹³⁴, Paolo Machi¹³⁵, Gianmarco Bernava¹³⁵, Mollie McDermott¹³⁶, Dawn Kleindorfer¹³⁶,

Ken Wong¹³⁷, Mary S.Patterson¹³⁸, Jose Antonio Fiorot¹³⁹, Vikram Huded¹⁴⁰, William Mack¹⁴¹, Matthew Tenser¹⁴¹, Clifford Eskey¹⁴², Sumeet Multani¹⁴³, Michael Kelly¹⁴⁴, Vallabh Janardhan¹⁴⁵, Oriana Cornett¹⁴⁶, Varsha Singh¹⁴⁶, Yuichi Murayama¹⁴⁷, Maxim Mokin¹⁴⁸, Pengfei Yang¹⁵, Xiaoxi Zhang¹⁵, Congguo Yin¹⁴⁹, Hongxing Han¹⁵⁰, Ya Peng¹⁵¹, Wenhao Chen¹⁵², Roberto Crosa¹⁵³, Michel Eli Frudit⁴⁶, Jeyaraj D.Pandian¹⁵⁴, Anirudh Kulkarni¹⁵⁴, Yoshiki Yagita^{155#}, Yohei Takenobu^{156#}, Yuji Matsumaru^{157#}, Satoshi Yamada^{158#}, Ryuhei Kono^{159#}, Takuya Kanamaru^{160#}, Hidekazu Yamazaki^{161#}, Manabu Sakaguchi^{162#}, Kenichi Todo^{163#}, Nobuaki Yamamoto^{164#}, Kazutaka Sonoda^{165#}, Tomoko Yoshida^{166#}, Hiroyuki Hashimoto^{167#}, Ichiro Nakahara^{168#}, Elena Cora¹⁶⁹, David Volders¹⁶⁹, Celina Ducroux⁶⁶, Ashkan Shoamanesh¹¹², Johanna Ospel⁶⁰, Artem Kaliev², Saima Ahmed^{170**}, Umair Rashid^{170**}, Leticia C. Rebello¹⁷¹, Vitor Mendes Pereira¹³³, Robert Fahed⁶⁷, Michael Chen¹¹¹, Sunil A Sheth⁷⁵, Lina Palaiodimou¹⁷², Georgios Tsivgoulis¹⁷², Ronil Chandra¹⁷³, Feliks Koyfman¹⁷⁴, Thomas Leung¹⁷⁵, Houman Khosravani¹⁷⁶, Sushrut Dharmadhikari¹⁷⁷, Giovanni Frisullo¹⁷⁸, Paolo Calabresi¹⁷⁸, Alexander Tsiskaridze¹⁷⁹, Nino Lobjanidze¹⁷⁹, Mikayel Grigoryan¹⁸⁰, Anna Czlonkowska¹⁸¹, Diana Aguiar de Sousa¹⁸², Jelle Demeestere¹⁸³, Conrad Liang¹⁸⁴, Navdeep Sangha¹⁸⁵, Helmi L.Lutsep¹⁸⁶, Óscar Ayo-Martín¹⁸⁷, Antonio Cruz-Culebras¹⁸⁸, Anh D.Tran⁴⁰, Chang Y.Young¹⁸⁹, Charlotte Cordonnier¹⁸⁹, Francois Caparros¹⁸⁹, Maria Alonso De Lecinana¹⁹⁰, Blanca Fuentes¹⁹⁰, Dileep Yavagal¹⁶⁵, Tudor Jovin⁷, Laurent Spelle¹², Jacques Moret¹², Pooja Khatri¹³⁸, Osama Zaidat¹³⁸, Jean Raymond⁶⁶, Sheila Martins¹⁹², Thanh Nguyen^{2*}

*On behalf of the SVIN COVID-19 Global Registry, the Middle East North Africa Stroke Interventional Neurotherapies Organization (MENA-SINO)** and Japanese Vascular and Interventional Neurology Society(JVIN)#*

AFFILIATIONS

¹Grady Memorial Hospital, Atlanta, USA; ²Boston Medical Center, USA; ³Alexandria University Hospital, Egypt; ⁴Osaka National Hospital, Japan; ⁵Xinqiao Hospital of the Army Medical University, China; ⁶Tabriz University, Iran; ⁷Cooper University Hospital, USA; ⁸New York University, USA; ⁹Kobe City Medical Center, Japan; ¹⁰Fondation Ophtalmologique Adolphe de Rothschild, France; ¹¹Hospices Civils de Lyon, France; ¹²Hôpital Bicetre, Paris, France; ¹³Royal Adelaide Hospital, Australia; ¹⁴Hôpitaux Universitaires de Strasbourg, France; ¹⁵Changhai Hospital, Shanghai, China; ¹⁶Royal Prince Alfred Hospital, Sydney, Australia; ¹⁷Yijishan Hospital of Wannan Medical College, China; ¹⁸Hospital Clinic de Barcelona, Spain; ¹⁹Hospital Clínico Universitario, Valladolid, Spain; ²⁰University Hospital Basel, Switzerland; ²¹Clínica Sagrada Familia, Buenos Aires, Argentina; ²²Centro Hospitalar Universitário de São João, Portugal; ²³Hospital Geral de Fortaleza, Brazil; ²⁴Careggi University Hospital, Florence, Italy; ²⁵University Hospital Bern, Switzerland; ²⁶Swedish Medical Center, USA; ²⁷MAX Superspecialty Hospital, India; ²⁸Memorial Neuroscience Institute, Florida; ²⁹University Hospital Heidelberg, Germany; ³⁰University of Iowa, USA; ³¹Valley Baptist Medical Center, Harlingen, Texas, USA; ³²University of Cape Town, South Africa; ³³Hôpital Foch, France; ³⁴Royal Melbourne Hospital, Australia; ³⁵University of Washington, Seattle, USA; ³⁶Universitätsklinikum Hamburg-Eppendorf, Germany; ³⁷People's 115 Hospital, Vietnam; ³⁸IMS Tokyo-Katsushika General Hospital, Japan; ³⁹Affiliated Hangzhou First People's Hospital, China; ⁴⁰Hue Central Hospital, Vietnam; ⁴¹Erlanger Medical Center,

USA; ⁴²Rutgers University, USA; ⁴³Miami Cardiac and Vascular Institute, USA; ⁴⁴Nottingham University Hospitals, United Kingdom; ⁴⁵Clínica Alemana, Universidad del Desarrollo, Chile; ⁴⁶Universidade Federal de Sao Paulo, Brazil; ⁴⁷Hospital Israelita Albert Einstein, Brazil; ⁴⁸Hackensack Meridian Health, New Jersey, USA; ⁴⁹Kyorin University, Japan; ⁵⁰Yokohama Brain and Spine Center, Japan; ⁵¹Iwate Prefectural Central Hospital, Japan; ⁵²Japanese Red Cross Kyoto Daiichi Hospital, Japan; ⁵³Kyoto Second Red Cross Hospital, Japan; ⁵⁴Japanese Red Cross Kumamoto Hospital, Japan; ⁵⁵Kohnan Hospital, Japan; ⁵⁶Maine Medical Center, USA; ⁵⁷Beaumont Hospital, Ireland; ⁵⁸Hopital Enfant Jesus, Canada; ⁵⁹New Haven Hospital, USA; ⁶⁰University of Calgary, Canada; ⁶¹University Hospital Salzburg, Austria; ⁶²Emory University School of Medicine, USA; ⁶³Valley Hospital, New Jersey, USA; ⁶⁴University Hospital Germans Trias i Pujol, Barcelona, Spain; ⁶⁵Lau Medical Center, Beirut, Lebanon; ⁶⁶CHU Montreal, Canada; ⁶⁷University of Ottawa, Canada; ⁶⁸University of South Alabama, USA; ⁶⁹University of Massachusetts Medical Center, USA; ⁷⁰University of Maryland, USA; ⁷¹Riverside Regional Medical Center, Virginia, USA; ⁷²UT Southwestern, Dallas, USA; ⁷³Henry Ford Health System, Detroit, USA; ⁷⁴Metropolitan Hospital, Piraeus, Greece ; ⁷⁵UTHealth McGovern Medical School, Houston, USA; ⁷⁶SUNY Upstate Medical University Hospital, USA; ⁷⁷University Hospital Centre Zagreb, Croatia; ⁷⁸Westchester Medical Center, USA; ⁷⁹Wuhan No.1 Hospital, China; ⁸⁰Affiliated Hospital of Southwest Medical University, China; ⁸¹Maoming City Hospital, China; ⁸²Shaw Shaw Hospital, China; ⁸³Sichuan Mianyang 404th Hospital, China; ⁸⁴University Clinical Hospital Center Sestre Milosrdnice, Croatia; ⁸⁵CHU Nantes, France; ⁸⁶University of California San Francisco, USA; ⁸⁷King Fahad Hospital of the University, Saudi Arabia; ⁸⁸King Saud University, Saudi Arabia; ⁸⁹Banner Desert Medical Center, USA; ⁹⁰Ajou University Hospital, Korea; ⁹¹Kyemyung University, Korea; ⁹²Kyungpook National University Hospital, Korea; ⁹³Gachon University Gil Hospital, Korea; ⁹⁴Konkuk University Hospital, Korea; ⁹⁵St. Louis University, USA; ⁹⁶Texas Tech University, USA; ⁹⁷University of Miami, USA; ⁹⁸UCLA, USA; ⁹⁹Thomas Jefferson University Hospital, USA; ¹⁰⁰Hospital Sao Jose, Brazil; ¹⁰¹Eskisehir Osmangazi University, Turkey; ¹⁰²Saga-ken Medical Centre Koseikan, Japan; ¹⁰³Saitama Medical Center, Japan; ¹⁰⁴Nara City Hospital, Japan; ¹⁰⁵Toyonaka Municipal Hospital, Japan; ¹⁰⁶Kagoshima City Hospital, Japan; ¹⁰⁷Japanese Red Cross Matsue Hospital, Japan; ¹⁰⁸Shiroyama Hospital, Japan; ¹⁰⁹Niigata City General Hospital, Japan; ¹¹⁰Sugimura Hospital, Kumamoto, Japan; ¹¹¹Rush University Medical Center, USA; ¹¹²McMaster University, Canada; ¹¹³Ribeirão Preto Medical School, Brazil; ¹¹⁴Shahid Beheshti University, Iran; ¹¹⁵Khoula Hospital, Ministry of Health, Oman; ¹¹⁶Hamad Medical Corporation, Qatar; ¹¹⁷Mount Sinai Health System, New York, USA; ¹¹⁸Cleveland Clinic Abu Dhabi, UAE; ¹¹⁹WellStar Health, USA; ¹²⁰Rambam Health Care, Israel; ¹²¹General Hospital Dr. Soetomo, Indonesia; ¹²²Istanbul Aydin University, Turkey; ¹²³Siriraj Hospital, Thailand; ¹²⁴Zanjan University, Iran; ¹²⁵Isfahan University, Iran; ¹²⁶Qom University, Iran; ¹²⁷Royal North Shore Hospital, Australia; ¹²⁸Christchurch Hospital, New Zealand; ¹²⁹Tufts Medical Center, USA; ¹³⁰Lahey Health, USA; ¹³¹Instituto de Neurocirugia Dr. Asengo, Chile; ¹³²National Institute of Neurological Sciences of Lima, Peru; ¹³³University of Toronto, Canada; ¹³⁴University of Texas San Antonio, USA; ¹³⁵University Hospitals of Geneva, Switzerland; ¹³⁶University of Michigan, USA; ¹³⁷Royal London Hospital, United Kingdom; ¹³⁸Bon Secours

Mercy Health, USA; ¹³⁹Hospital-Estadual Central, Brazil; ¹⁴⁰NH Mazumdar Shaw Medical Center, India; ¹⁴¹University of Southern California, USA; ¹⁴²Dartmouth Medical Center, USA; ¹⁴³Bayhealth Medical Center, USA; ¹⁴⁴University of Saskatchewan, Canada; ¹⁴⁵Medical City Plano Texas, USA; ¹⁴⁶St. Joseph's University Medical Center, USA; ¹⁴⁷Jikei University School of Medicine, Japan; ¹⁴⁸University of South Florida, USA; ¹⁴⁹Affiliated Hangzhou First People's Hospital, China; ¹⁵⁰Linyi City People Hospital, China; ¹⁵¹First People's Hospital, China; ¹⁵²Zhangzhou Municipal Hospital, China; ¹⁵³Centro Endovascular Neurológico Médica Uruguaya, Uruguay; ¹⁵⁴Christian Medical College, India; ¹⁵⁵Kawasaki Medical School, Japan; ¹⁵⁶Osaka Red Cross Hospital, Japan; ¹⁵⁷University of Tsukuba, Japan; ¹⁵⁸Saiseikai Central Hospital, Japan; ¹⁵⁹Kinikyochuo Hospital, Japan; ¹⁶⁰NTT Medical Center, Japan; ¹⁶¹Yokohama Shintoshu Neurosurgical Hospital, Japan; ¹⁶²Osaka General Medical Center, Japan; ¹⁶³Osaka University Graduate School of Medicine, Japan; ¹⁶⁴Tokushima University Graduate School of Biomedical Sciences, Japan; ¹⁶⁵Saiseikai Fukuoka General Hospital, Japan; ¹⁶⁶Tane General Hospital, Japan; ¹⁶⁷Osaka Rosai Hospital, Japan; ¹⁶⁸Fujita Health University School of Medicine, Japan; ¹⁶⁹Dalhousie University, Canada; ¹⁷⁰Lahore General Hospital, Pakistan; ¹⁷¹Hospital Brasilia, Brazil; ¹⁷²National & Kapodistrian University of Athens, Greece; ¹⁷³Monash Medical Center, Australia; ¹⁷⁴New York-Presbyterian Queens, USA; ¹⁷⁵Prince of Wales Hospital, Hong Kong; ¹⁷⁶Sunnybrook Health Sciences Centre, Canada; ¹⁷⁷Baptist Health, Arkansas, USA; ¹⁷⁸Fondazione Policlinico Universitario A.Gemelli, Italy; ¹⁷⁹Ivane Javakhishvili Tbilisi State University, Georgia; ¹⁸⁰Adventist Health Glendale, USA; ¹⁸¹Institute Psychiatry and Neurology, Poland; ¹⁸²Hospital de Santa Maria, Portugal; ¹⁸³Leuven University Hospital, Belgium; ¹⁸⁴Kaiser Permanente, California; ¹⁸⁵Oregon University, USA; ¹⁸⁶Complejo Hospitalario Universitario de Albacete, Spain; ¹⁸⁷Hospital Universitario Ramon y Cajal, Unidad de Ictus, Spain; ¹⁸⁸Asan Medical Center, Korea; ¹⁸⁹CHU de Lille, France; ¹⁹⁰La Paz University Hospital, Madrid, Spain; ¹⁹¹University of Cincinnati, USA; ¹⁹²Hospital de Clínicas de Porto Alegre, Brazil;

Keywords: COVID-19, stroke care, acute ischemic stroke, mechanical thrombectomy, intracranial hemorrhage, epidemiology

Disclosures:

Dr. Nguyen: Medtronic.

Dr. Nogueira: Stryker; Cerenovus/Neuravi; Ceretrieve.

Abstract

Background: The COVID-19 pandemic led to profound changes in the organization of health care systems worldwide.

Aims: We sought to measure the global impact of the COVID-19 pandemic on the volumes for mechanical thrombectomy, stroke, and intracranial hemorrhage hospitalizations over a three month period at the height of the pandemic (March 1 to May 31, 2020) compared with two control three month periods (immediately preceding and one year prior).

Methods: Retrospective, observational, international study, across 6 continents, 40 countries, and 187 comprehensive stroke centers. The diagnoses were identified by their ICD-10 codes and/or classifications in stroke databases at participating centers.

Results: The hospitalization volumes for any stroke, intracranial hemorrhage, and mechanical thrombectomy were 26,699, 4,002, and 5,191 in the three months immediately before versus 21,576, 3,540, and 4,533 during the first three pandemic months, representing declines of 19.2% (95%CI, -19.7 to -18.7), 11.5% (95%CI, -12.6 to -10.6), and 12.7% (95%CI, -13.6 to -11.8), respectively. The decreases were noted across centers with high, mid, and low COVID-19 hospitalization burden, and also across high, mid, and low volume stroke/ mechanical thrombectomy centers. High-volume COVID-19 centers (-20.5%) had greater declines in mechanical thrombectomy volumes than mid- (-10.1%) and low-volume (-8.7%) centers ($p < 0.0001$). There was a 1.5% stroke rate across 54,366 COVID-19 hospitalizations. SARS-CoV-2 infection was noted in 3.9% (784/20,250) of all stroke admissions.

Conclusion: The COVID-19 pandemic was associated with a global decline in the volume of overall stroke hospitalizations, mechanical thrombectomy procedures, and intracranial hemorrhage admission volumes. Despite geographic variations, these volume reductions were observed regardless of COVID-19 hospitalization burden and pre-pandemic stroke/ mechanical thrombectomy volumes.

Funding: None

Introduction

In December 2019, a novel highly pathogenic virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused an infectious disease involving multiple organ systems termed coronavirus disease 2019 (COVID-19). COVID-19 holds a unique balance between high transmissibility and low-to-moderate morbidity and mortality that has led to a nearly universal spread with devastating consequences worldwide. On March 11, 2020, the World Health Organization declared a global pandemic as COVID-19 hospitalizations and emergency medical system activations increased. As a potential consequence of its neurotropism as well as the inflammatory, immunological, and coagulation disorders, COVID-19 has been reported in association with a broad array of neurological disorders including encephalitis, Guillain-Barre syndrome, seizures, ischemic and hemorrhagic strokes.¹ Some groups reported an increase in cryptogenic strokes involving young patients with SARS-CoV-2 infection, possibly in association with endothelial inflammation and thrombotic diathesis.²⁻⁷ Others reported a decline in the rates of stroke hospitalizations and the proportion of patients receiving reperfusion therapies (intravenous thrombolysis[IVT] and/or mechanical thrombectomy[MT]) for acute ischemic stroke(AIS). Notably, many of these studies originated from global epicenters for the pandemic supporting the notion that the indirect or collateral damage of COVID-19 on systems of care has had a greater impact on stroke patients than the viral infection itself.^{3,5,8-12} However, most of these reports were limited to regional or country-specific analyses, and thus, the extent to which the COVID-19 outbreak has impacted global stroke systems of care has not been previously assessed. Importantly, given the profound benefit of MT in acute ischemic stroke, the global public health impact of such declines, if confirmed, adds to the devastation caused by COVID-19.

Aims and Hypotheses

We conducted an international, observational study on the impact of the COVID-19 pandemic on stroke care at the height of the COVID-19 pandemic. Our primary aim was to evaluate the effect of COVID-19 on stroke care as measured by the changes in volumes for overall stroke hospitalizations, ischemic stroke/transient ischemic attacks (TIA) admissions, ICH admissions, and MT procedures across the pre-pandemic and pandemic periods in a multinational pool of comprehensive stroke centers (CSC). The study compared the three initial months of the pandemic (March 1, 2020, to May 31, 2020) with (1) the immediately preceding months (December 2019 to

February 2020 for overall volume and November 2019 to February 2020 for monthly volume) as the primary analysis and (2) the equivalent three months in the previous year (March 1, 2019, to May 30, 2019) as the secondary analysis. The reasons for this analytic hierarchy was an a priori expectation that the volumes for both stroke admissions and MT procedures would increase over time due to the growing evidence supporting the broader utilization of MT.¹³⁻¹⁵ While the primary analysis provided a realistic picture of stroke care utilization prior to COVID-19, the secondary analysis allowed for the assessment for potential seasonal variations.¹⁶

We hypothesized that in the face of the pandemic's strain on healthcare infrastructure, (1) a reduction in all four aforementioned measurements of stroke care would take place over the pandemic, (2) centers with higher COVID-19 inpatient volumes would report greater decreases in stroke admissions and MT procedure volumes, (3) the degree of decline in stroke admissions and MT procedure volumes would be less profound in high-volume compared to low-volume stroke centers, (4) a geographic variation would exist in the intensity of decline in stroke care.

METHODS

Data are available upon request to the corresponding author.

Study Design

This was a cross-sectional, observational, retrospective study evaluating monthly and weekly volumes of consecutive patients hospitalized with a diagnosis of COVID-19, stroke, MT, and ICH. The diagnoses were identified by their related ICD-10 codes (primary, secondary, or tertiary discharge codes) and/or classifications in stroke databases at participating centers.

Setting and Participants

Data were collected from collaborators of the Society of Vascular and Interventional Neurology, the Middle East North Africa Stroke and Interventional Neurotherapies Organization, the Japanese Vascular & Interventional Neurology Society, and academic partners from six continents, 40 countries, and 187 CSCs. To reduce bias, only

centers providing the full dataset required for any given analysis were included in that specific analysis. Centers were screened for potential confounders that could explain unexpected changes in volumes. One center in Vietnam was excluded from the MT secondary analysis due to an abrupt increase in volume attributed to the purchase of automated imaging software. One center in Brazil was excluded from the stroke admission analysis because it became the designated center for stroke patients, resulting in tripling of their volumes.

Study Variables and Outcomes Measures

The overall and mean monthly volumes for stroke hospitalizations, admissions for ischemic stroke/ TIA, admissions for ICH and MT procedures were compared across the pandemic and pre-pandemic periods for the overall population and across the low, mid, and high volume strata based on mean monthly volume tertiles for COVID-19 hospitalizations (≤ 10.6 vs. >10.6 to 103.6 vs. >103.6 COVID-19 admissions/month), stroke admissions (≤ 46.2 vs. >46.2 to 78.4 vs. >78.4 stroke admissions/month) and MT interventions (≤ 4.8 vs. >4.8 to 11.4 vs. >11.4 procedures/month).

Statistical Analysis

We first compared overall hospital volumes for stroke admissions (overall stroke, ischemic, and ICH) and MT procedures between the pre-pandemic and the pandemic period. For this analysis, the percentage change in the number of admissions or procedures between the two time periods was calculated. The three month pre-pandemic period was restricted to three months before the pandemic (December 1, 2019, to February 29, 2020) to keep it consistent with the three months during the COVID-19 pandemic group (March 1, 2020, to May 31, 2020). The 95% confidence intervals for percentage change were calculated using the Wilson procedure without continuity correction. The analyses were repeated within each tier (low, mid, and high) of centers classified based on COVID-19 hospitalizations, stroke admissions, and MT procedures. The relative percentage change in overall volume between low, mid, and high-volume centers was tested using the z-test of proportion. We also looked at relative change in overall volume by continent.

In the second analysis, we compared monthly hospital volumes (admissions or procedures/hospital/month) for our outcome of interests between the pre-pandemic and the pandemic period. For the pre-pandemic period, for each hospital, the monthly hospital volume was calculated from November 2019 to February 2020 and compared

to the monthly hospital volume during the pandemic period (March 1, 2020 - May 31, 2020). The data were analyzed in a mixed design using a repeated-measures analysis of variance (PROC MIXED analysis in SAS) to account for the paired data structure and potential covariates. The auto-regressive, compound symmetrical, and unstructured variance-covariance matrix structures were analyzed for the best model determined by Akaike's Information Criterion. The unstructured matrix was the best fit and used for most analyses. The monthly hospital volume analysis was adjusted for peak COVID-19 volume for each country and the continent. Estimated marginal means were calculated using the LSMEANS statement in PROC MIXED. Similar to the overall volume analysis, monthly volume analysis was repeated within low, mid and high tier of centers based on their COVID-19 hospitalizations, stroke admissions and, MT procedures as well as by the continent.

Finally, for our secondary objective, we compared the relative change in overall volume and change in monthly hospital volume during the COVID-19 pandemic and corresponding three months from 2019 (March 1, 2019, to May 31, 2019). All data were analyzed using SAS version 9.4 (SAS Institute), and the significance level was set at a *P*-value of <0.05.

Funding and Ethics

This was an investigator-initiated project with no funding. The first and last authors wrote the first draft of the manuscript with subsequent input of all co-authors. The institutional review boards from the coordinating sites (Emory University and Boston University) considered that the investigators did not have access to protected health information and thus no IRB oversight was required since the study did not meet the federal description of human subject research. This study is reported in accordance with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement.

RESULTS

A total of 16,141, 26,699 and 21,576 stroke hospitalizations (overall $n=64,416$) and 3,397, 5,191 and 4,533 MT procedures (overall $n=13,121$) were included across the three month prior year, three month immediately pre-pandemic, three month pandemic periods, respectively.

Overall Stroke Hospitalization Volumes

In the primary analysis of overall volume, stroke hospitalization volumes were 26,699 admissions in the three months immediately before compared to 21,576 admissions during the pandemic, representing a 19.2% (95%CI, -19.7 to -18.7, N=121 sites) drop, Table 1. The stroke hospitalization decline had a geographic variation: Asia, -20.5% (95%CI, -21.2 to -19.8); North America, -20.6% (95%CI, -21.4 to -19.7); Europe, -11.2% (95%CI, -12.3 to -10.1); South America, -15.9% (95%CI, -17.9 to -14.0), Oceania, -11.6% (95%CI, -14.4 to -9.3); Africa, -48.1% (95%CI, -55.8 to -40.5), Table S1. In an analysis of monthly volume, after adjustment for peak COVID-19 volume by country and continent, the number of hospitalizations for stroke/month/hospital (adjusted mean (SE)) declined from 76.4(12.3) pre-pandemic to 64.2(12.0) during the pandemic ($p<0.0001$), Table 1.

Mechanical Thrombectomy (MT) Procedural Volumes

MT volume data was represented by 176 centers in the primary analysis with 5,191 procedures in the 3 months immediately preceding compared to 4,533 procedures during the first three months of the pandemic, representing a 12.7% (95%CI, -13.6 to -11.8) decline, Table 2. The volume reduction varied: Asia, -9.8% (95%CI, -11.3 to -8.4); North America, -14.5% (95%CI, -16.2 to -12.9); Europe, -14.4% (95%CI, -16.4 to -12.6); South America, -12.4% (95%CI, -19.0 to -7.9), Oceania, -9.4% (95%CI, -13.4 to -6.5); Africa, -21.2% (95%CI, -37.8 to -10.7), Table S2. The adjusted mean (SE) number of MT procedures/month/center decreased from 10.9 (1.3) pre-pandemic to 9.8 (1.3) during the pandemic ($p<0.0001$), Table 2. There were 120 centers that reported concomitant monthly data on stroke admission and MT volume. The adjusted mean (SE) monthly proportion of MT relative to stroke admissions remained stable across the pre-pandemic and pandemic periods (17.8 [2.2] % vs. 18.5 [2.2] %, respectively; $p=0.150$). This proportional stability in MT performance was consistent across all COVID-19 and MT hospitalization volumes strata, Table S3.

Ischemic Stroke/TIA and Intracranial Hemorrhage Volumes

The ischemic stroke/TIA admission volumes declined from 19,882 to 16,884 patients across the three months preceding versus the pandemic months, corresponding to a 15.1% (95%CI, -15.6 to -14.6, N=113 sites) reduction

with an adjusted mean (SE) number of ischemic stroke or TIA/month/center decreasing from 64.3(6.8) to 55.6(6.5) across the two epochs ($p < 0.0001$). Complete results are presented in Table S4.

The ICH admission volumes, submitted by 100 sites, decreased from 4,002 to 3,540 patients across the three months immediately before versus the pandemic months, representing an 11.5% (95%CI, -12.6 to -10.6) decline with the adjusted mean (SE) number of hospitalizations for ICH/month/center dropping from 13.4(2.6) to 11.6(2.6), across the two periods ($p < 0.0001$), Table S5.

Changes in Stroke Care Metrics During the Pandemic as a Function of COVID-19 Hospitalization Volumes

Figures 1 and 2 provide the weekly volume of stroke admissions (ischemic and hemorrhagic), MT, and COVID-19 hospitalizations. COVID-19 hospital weekly volume data was available for 131 centers. There was an early peak of 1,235 COVID-19 hospitalizations in February which predominantly originated from one hospital in Wuhan, China. Significant reductions in the mean monthly volumes were seen for all stroke care metrics across all tertiles of low, mid, and high COVID-19 hospitalization volumes. The exception was ICH volumes in high-volume COVID-19 centers which did not show a statistically significant difference (Tables 1, S4, S5). High-volume COVID-19 centers (-20.5%; 95%CI, -22.6 to -18.6) had greater declines in MT volumes than mid-(-10.1%; 95%CI, -11.8 to -8.6; $p < 0.0001$) and low-volume (-8.7%; 95%CI, -10.7 to -7.1; $p < 0.0001$) COVID-19 centers, Table 2. Likewise, high-volume COVID-19 centers (-22.7%; 95%CI, -23.7 to -21.8) had greater reductions in stroke hospitalization volumes than mid- (-19.8%; 95%CI, -20.8 to -19.0; $p < 0.0001$) and low-volume (-12.6%; 95%CI, -13.4 to -11.9; $p < 0.0001$) COVID-19 centers, Table 1.

Changes in Stroke Care Metrics During the Pandemic as a Function of Stroke Center MT and Admission Volumes

Significant declines in the mean monthly volumes were observed for all stroke/MT metrics across low-, mid- and high-volume stroke/MT centers except MT volumes in low-volume MT centers showed a trend in decline (Tables 1, 2, S4, S5). Mid-volume stroke centers (-17.6%; 95% CI, -18.5 to -16.7) demonstrated greater decreases in stroke admission volumes than low-volume (-15.1%; 95%CI, -16.3 to -13.9; $p < 0.0001$) centers, Table 1.

Secondary objective

Table S6 depicts the volumes for overall stroke, ischemic stroke/TIA, ICH hospitalizations and MT procedures during the first three months of the pandemic versus the corresponding period in the prior year. Compared to the prior year, there were significant declines in the monthly volumes for stroke and ischemic stroke/TIA admissions but not for ICH and MT.

Associations Between the Diagnoses of COVID-19 and Stroke

There were 124 centers that reported patients with concomitant stroke (all subtypes) and SARS-CoV-2 infection. To reduce bias, 13 centers with no COVID-19 patients were excluded, leaving 111 eligible centers. A diagnosis of any stroke was present in 791 of 54,366 (1.45%; 95% CI, 1.35 to 1.55) COVID-19 hospitalizations. There was geographic variation with incidences ranging from 0.43% (95%CI, 0.08-2.38) in Oceania to 11.9% in South America (95%CI, 10.05-14.03), Table S7. Conversely, 784 of the 20,250 (3.9%, 95% CI, 3.61-4.14) overall stroke admissions were diagnosed with COVID-19 with proportions varying from 0.14% (95%CI, 0.03-0.78) in Oceania to 8.93% in South America (95%CI, 7.54-10.55), Table S8.

Discussion

We noted a significant global decline in all measured stroke care metrics in the current study including the numbers of mechanical thrombectomy procedures (-12.7%), overall stroke admissions (-19.2%), ischemic stroke/TIA admissions (-15.1%), and intracranial hemorrhage hospitalization volumes (-11.5%) during the COVID-19 pandemic as compared to the immediately preceding three months, confirming our primary hypothesis. Volume reductions were also seen in relation to the equivalent period in the prior year for stroke admissions and ischemic/TIA admissions. The intensity of the decline was more pronounced when comparing the pandemic period with the immediate 3 months prior than with the same months in 2019 (MT: 12.7% vs.6.0%; stroke admissions: 19.2% vs. 12%). This followed our a priori expectations in face of the expansions in MT indications along with its progressive but gradual global implementation in developed and developing countries.¹⁷ Interestingly, despite the absolute decrease in MT volumes, the proportion of MT relative to stroke admissions remained stable during the pandemic. While at first glance this might suggest that the intra-hospital workflow was

maintained, it is possible that this was not the case since one would actually expect an increase in the MT ratio relative to stroke admissions as many studies have now demonstrated that there was a preferential decline in patients presenting with milder strokes during the pandemic.^{4,11,18,19,23} The decreases in the amount of stroke care were noted across centers with high, mid, and low COVID-19 hospitalization burden, and also across high, mid, and low volume stroke and MT centers. As hypothesized, centers with higher COVID-19 inpatient volumes suffered more declines. Contrary to our expectations, the declines in stroke hospitalizations and MT volumes were more profound in mid-(and high-) volume than low-volume stroke centers. This might be related to the fact that larger centers were more likely to become the preferred destination for COVID-19 referrals leading to capacity issues. Finally, we confirmed a broad geographic variation in the patterns of stroke care decline.

Our results align with recent reports emphasizing the collateral effects of the COVID-19 pandemic on stroke systems of care from China,^{10,18} Spain,^{3,19} Italy,^{20,21} France,^{9,22} Germany,¹² Brazil,²³ Canada,²⁴ and United States,^{5,11,25,26} showing declines in the volumes for MT, IVT and stroke hospitalizations over the pandemic (Table S9-11). Some of these studies also reported delays in hospital arrival times^{18,20,25} and treatment workflow.^{9,20} Our analysis adds to the growing literature regarding the collateral damage of COVID-19 on stroke care with the advantage of providing a broader global perspective. While the overall data clearly points to a significant reduction in the quantity of stroke care provided during the pandemic, it also depicts variations within and across the different regions reflecting the diversity in the epidemiology for COVID-19 as well as in the socio-cultural behaviors, healthcare logistics, and infrastructure encountered across the globe. Indeed, our study demonstrated important geographic variations in the proportional declines for both stroke hospitalization and MT volumes. Notably, our analysis may have underestimated the impact of geographic disparities in healthcare resources and related socio-economic factors as we only included thrombectomy capable centers which are known to have better infrastructure than the more commonly found primary stroke centers. Moreover, there was a higher geographic variation in the proportional decline for stroke hospitalization (Asia, -20.5%; North America, -20.6%; Europe, -11.2%; South America, -15.9%, Oceania, -11.6%; Africa, -48.1%) than mechanical thrombectomy (Asia, -9.8%; North America, -14.5%; Europe, -14.4%; South America, -12.4%, Oceania, -9.4%; Africa, -21.2%) volumes. As seen in relation to the

stability in the MT ratio relative to stroke admissions, this might have been related to the favored decline in milder strokes over the course of the pandemic.^{4,11,18,19,23}

Given the growing evidence supporting the association between COVID-19 and thromboembolic events, it would be expected that the stroke incidence would rise at the precipice of the pandemic. Several factors may explain this paradoxical global decrease in stroke, MT, and ICH volumes observed in this study. As this decline in stroke volume was seen in centers with low or non-existent COVID-19 hospitalizations, hospital access due to the COVID-19 hospitalization burden was unlikely a major factor.¹² As elective surgeries were canceled with the pandemic, a decrease in perioperative stroke may have played a role. It is also conceivable that the environmental situation of a lockdown, with improved patient behaviors or medication compliance, may be protective in decreasing vascular events.²⁷ A reduction in exposure to other common viruses that may play a role in triggering vascular events may have also reduced stroke risk. However, it is unlikely that true incidence of stroke declined and more likely the behavioral and infrastructural changes related to the pandemic led to a reduction of admission of acute ischemic stroke patients, especially during the initial phases of public lockdown. Fear of contracting SARS-CoV-2 may have led many patients with milder stroke presentations to avoid seeking medical attention.^{4,11,18,19,23} Physical distancing measures may have prevented patients from the timely witnessing of a stroke.

Our subgroup of 111 centers including 54,366 COVID-19 hospitalizations is the largest sample reporting the concomitant diagnoses of stroke and SARS-CoV-2 infection to date. Our 1.45% stroke rate in COVID-19 hospitalizations is similar to the pooled incidence of 1.1 to 1.2% (range, 0.9%-2.7%) of hospitalized COVID-19 patients.^{28,29} Some variation in the proportions are expected given the different definitions (all strokes vs. ischemic only) and populations involved (all hospitalized vs. severely infected only) across studies. We also provide a new perspective on this relationship by reporting an incidence of 3.9% (784/20,250) for SARS-CoV-2 infection across all stroke admissions among centers with documented COVID-19 hospitalization.

Study strengths and limitations

The strength of our study was the large volume of patients (n=64,416) and a high number of centers (n=187) contributing data from a diverse population across six continents and 40 countries. Our study contained centers with high and low COVID-19 hospitalization admissions, high and low stroke admission, and MT volumes, permitting the generation of multiple hypotheses and endpoints.

The limitations of this study were that the diagnosis of stroke/TIA/ICH, thrombectomy volume in some centers was obtained using hospital ICD administrative codes, and verification for accurate diagnosis was not universally undertaken. The centers contributing to these data have systems in place to track stroke admissions, thus, the relative changes in volume from this analysis are likely accurate. Details on patient-level data including demographics, stroke subtypes, and clinical outcomes were not collected as these were not the focus of the study. As with any other study, our data may underestimate true rates of concomitant SARS-CoV2 infection with a stroke diagnosis depending on the frequency of testing at each site and across the study period. The definition of the pandemic period was arbitrary since the outbreak started and peaked at different times at different locations. After adjustment for peak COVID-19 volume for each country and continent, the monthly volume declines were retained for all stroke metrics (stroke hospitalization, MT, ICH). As the penetration of MT remains limited in many countries,¹⁷ some geographic regions were not represented (i.e., central Africa). We did not collect data on the timing or intensity of social distancing policies including lockdown implementation across the different localities which likely played an important role in the reported stroke care decline. Finally, the sampling varied with the availability of complete data in each subset of the analysis.

Summary

There was a significant global decline in mechanical thrombectomy and stroke admissions over the 3 months studied during the pandemic. These decreases were seen regardless of COVID-19 admission burden, individual pre-pandemic stroke, and MT volumes. Thus, it is critical to expeditiously raise public awareness to prevent the additional healthcare consequences associated with the lack of stroke treatment. These findings can inform regional stroke networks preparedness²⁹ in the face of a future pandemic or anticipated surge of COVID-19 cases in

order to ensure that the access and quality of stroke care remains preserved despite the crises imposed by the continuous spread of the virus.

Funding: None

Peer Review Version

References:

1. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruville DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. *JAMA Neurol.* 2020;77:1018-27.
2. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J Med.* 2020;382:e60.
3. Rudilosso S, Laredo C, Vera V, Vargas M, Renú A, Llull L, Obach V, Amaro S, Urrea X, Torres F, Jiménez-Fàbrega FX, Chamorro Á. Acute Stroke Care Is at Risk in the Era of COVID-19: Experience at a Comprehensive Stroke Center in Barcelona. *Stroke.* 2020 ;51:1991-5.
4. Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, Henninger N, Trivedi T, Lillemo K, Alam S, Sanger M, Kim S, Scher E, Dehkharghani S, Wachs M, Tanweer O, Volpicelli F, Bosworth B, Lord A, Frontera J. SARS-CoV-2 and Stroke in a New York Healthcare System. *Stroke.* 2020;51:2002-11.
5. Onteddu SR, Nalleballe K, Sharma R, Brown AT. Underutilization of health care for strokes during the COVID-19 outbreak. *Int J Stroke.* 2020;15:NP9-NP10.
6. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. *Lancet.* 2020;395:1417-18.
7. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood.* 2020;135:2033-40.
8. Kansagra AP, Goyal MS, Hamilton S, Albers GW. Collateral Effect of Covid-19 on Stroke Evaluation in the United States. *N Engl J Med.* 2020;383:400-401.
9. Kerleroux B, Fabacher T, Bricout N, Moïse M, Testud B, Vingadassalom S, Ifergan H, Janot K, Consoli A, Ben Hassen W, Shotar E, Ognard J, Charbonnier G, L'Allinec V, Guédon A, Bolognini F, Marnat G, Forestier G, et al. Mechanical Thrombectomy for Acute Ischemic Stroke Amid the COVID-19 Outbreak: Decreased Activity, and Increased Care Delays. *Stroke.* 2020;51:2012-17.
10. Zhao J, Li H, Kung D, Fisher M, Shen Y, Liu R. Impact of the COVID-19 Epidemic on Stroke Care and Potential Solutions. *Stroke.* 2020;51:1996-2001.
11. Siegler JE, Heslin ME, Thau L, Smith A, Jovin TG. Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center. *J Stroke Cerebrovasc Dis.* 2020;29:104953.
12. Hoyer C, Ebert A, Huttner HB, Puetz V, Kallmünzer B, Barlinn K, Haverkamp C, Harloff A, Brich J, Platten M, Szabo K. Acute Stroke in Times of the COVID-19 Pandemic: A Multicenter Study. *Stroke.* 2020;51:2224-7.
13. Román LS, Menon BK, Blasco J, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. *Lancet Neurol.* 2018;17:895-904.
14. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med.* 2018;378:11-21.
15. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *N Engl J Med.* 2018;378:708-18.
16. Liao JN, Chao TF, Liu CJ, et al. Seasonal variation in the risk of ischemic stroke in patients with atrial fibrillation: A nationwide cohort study. *Heart Rhythm.* 2018;15:1611-16.

17. Martins SO, Mont'Alverne F, Rebello LC, et al. Thrombectomy for Stroke in the Public Health Care System of Brazil. *N Engl J Med*. 2020;382:2316-26.
18. Teo KC, Leung WCY, Wong YK, et al. Delays in Stroke Onset to Hospital Arrival Time During COVID-19. *Stroke*. 2020;51:2228-31.
19. Montaner J, Barragán-Prieto A, Pérez-Sánchez S, Escudero-Martínez I, Moniche F, Sánchez-Miura JA, Ruiz-Bayo L, González A. Break in the Stroke Chain of Survival due to COVID-19. *Stroke*. 2020;51:2307-14.
20. Baracchini C, Pieroni A, Viaro F, et al. Acute stroke management pathway during Coronavirus-19 pandemic. *Neurol Sci*. 2020;41:1003-5.
21. Morelli N, Rota E, Terracciano C, et al. The Baffling Case of Ischemic Stroke Disappearance from the Casualty Department in the COVID-19 Era. *Eur Neurol*. 2020;83:213-15.
22. Pop R, Quenardelle V, Hasiu A, Mihoc D, Sellal F, Dugay MH, Lebedinsky PA, Schluck E, LA Porta A, Courtois S, Gheoca R, Wolff V, Beaujeux R. Impact of the COVID-19 outbreak on acute stroke pathways - insights from the Alsace region in France. *Eur J Neurol*. 2020;27:1783-7.
23. Diegoli H, Magalhães PSC, Martins SCO, Moro CHC, França PHC, Safanelli J, Nagel V, Venancio VG, Liberato RB, Longo AL. Decrease in Hospital Admissions for Transient Ischemic Attack, Mild, and Moderate Stroke During the COVID-19 Era. *Stroke*. 2020;51:2315-21.
24. Bres Bullrich M, Fridman S, Mandzia JL, Mai LM, Khaw A, Vargas Gonzalez JC, Bagur R, Sposato LA. COVID-19: Stroke Admissions, Emergency Department Visits, and Prevention Clinic Referrals. *Can J Neurol Sci*. 2020;47:693-6.
25. Schirmer CM, Ringer AJ, Arthur AS, Binning MJ, Fox WC, James RF, Levitt MR, Tawk RG, Veznedaroglu E, Walker M, Spiotta AM; Endovascular Research Group (ENRG). Delayed presentation of acute ischemic strokes during the COVID-19 crisis. *J Neurointerv Surg*. 2020;12:639-42.
26. Uchino K, Kolikonda MK, Brown D, Kovi S, Collins D, Khawaja Z, Buletko AB, Russman AN, Hussain MS. Decline in Stroke Presentations During COVID-19 Surge. *Stroke*. 2020;51:2544-7.
27. American Heart Association's Mission: Lifeline and Get With The Guidelines Coronary Artery Disease Advisory Work Group and the Council on Clinical Cardiology's Committees on Acute Cardiac Care and General Cardiology and Interventional Cardiovascular Care*. Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic: AHA's Mission: Lifeline. *Circulation*. 2020;142:199-202.
28. Tan YK, Goh C, Leow AST, Tambyah PA, Ang A, Yap ES, Tu TM, Sharma VK, Yeo LLL, Chan BPL, Tan BYQ. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. *J Thromb Thrombolysis*. 2020;50:587-95.
29. Nguyen TN, Abdalkader M, Jovin TG, et al. Mechanical Thrombectomy in the Era of the COVID-19 Pandemic: Emergency Preparedness for Neuroscience Teams: A Guidance Statement From the Society of Vascular and Interventional Neurology. *Stroke*. 2020;51:1896-901.

Peer Review Version

Table 1. Stroke admissions overall and monthly volumes immediately before and during the COVID-19 pandemic.

	Overall volume				Monthly volume*			
	N	n1	n2	Change %(95%CI)	N	Immediately before	During COVID-19	P
Overall	119	26,699	21,576	-19.2(-19.7 - -18.7)	121	76.4(12.3)	64.2(12.0)	<0.0001
Hospital COVID-19 volume[†]								
Low	38	7,612	6,654	-12.6(-13.4 - -11.9)	38	62.4(31.4)	53.9(30.7)	0.002
Mid	31	7,495	6,008	-19.8(-20.8 - -19.0)	34	84.8(10.5)	71.0(8.7)	0.002
High	30	7,163	5,534	-22.7(-23.7 - -21.8)	33	90.1(9.8)	72.9(9.3)	<0.0001
Hospital Stroke volume[‡]								
Low	40	3,536	3,003	-15.1(-16.3 - -13.9)	40	28.7(2.6)	24.5(2.5)	<0.0001
Mid	37	6,804	5,609	-17.6(-18.5 - -16.7)	40	62.7(2.7)	53.1(3.3)	<0.0001
High	37	14,994	12,400	-17.3(-17.9 - -16.7)	41	134.1(21.6)	111.6(20.8)	<0.0001

Abbreviations: N=number of hospitals; n1=number of admissions immediately before COVID-19 pandemic; n2= number of admissions during COVID-19 pandemic; CI=confidence interval; SE=standard error

Note: The n1 is based on 3 months before (December 2019 to February 2020) COVID-19 pandemic.

*The monthly volume analysis is adjusted for peak COVID-19 volume for each country and the continent

[†]P: Low vs Mid=<0.0001; Low vs High=<0.0001; Mid vs High=<0.0001

[‡]P: Low vs Mid=0.001; Low vs High=0.002; Mid vs High=0.588

Table 2. Mechanical thrombectomy overall and monthly volumes immediately before and during the COVID-19 pandemic.

	Overall volume				Monthly volume*			
	N	n1	n2	Change % (95%CI)	N	Immediately before	During COVID-19	P
Overall	176	5,191	4,533	-12.7(-13.6 - -11.8)	173	10.9(1.3)	9.8(1.3)	<0.0001
Hospital COVID-19 volume[†]								
Low	44	952	869	-8.7(-10.7 - -7.1)	44	11.2(3.6)	10.5(3.5)	0.044
Mid	45	1,370	1,232	-10.1(-11.8 - -8.6)	45	11.7(1.2)	10.8(1.2)	0.004
High	45	1,602	1,273	-20.5(-22.6 - -18.6)	46	7.8(2.2)	5.7(2.2)	<0.0001
Hospital MT volume[‡]								
Low	59	459	412	-10.2(-13.4 - -7.8)	60	2.6(0.36)	2.3(0.36)	0.082
Mid	55	1,294	1,092	-15.6(-17.7 - -13.7)	55	8.1(0.46)	7.0(0.50)	0.0002
High	58	3,432	3,029	-11.7(-12.9 - -10.7)	58	18.8(1.8)	16.8(1.7)	0.0002

Abbreviations: N=number of hospitals; n1=number of procedures immediately before COVID-19 pandemic; n2= number of procedures during COVID-19 pandemic; CI=confidence interval; SE=standard error; MT=Mechanical Thrombectomy

Note: The n1 is based on 3 months before (December 2019 to February 2020) COVID-19 pandemic.

*The monthly volume analysis is adjusted for peak COVID-19 volume for each country and the continent

[†]P: Low vs Mid=0.259; Low vs High=<0.0001; Mid vs High=<0.0001

[‡]P: Low vs Mid=0.004; Low vs High=0.345; Mid vs High=0.0003

Acknowledgments

Patrick Nicholson,MD, Jasmine Johann,MSN,FNP-BC, Judith Clark,RN, Matt Metzinger,MBA,CPHQ, Jefferson,
Kamini Patel,RN,MBA, Janis Ginnane,RN.

Peer Review Version